Intensity Therapeutics (INTS) Non-Current Assets (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Non-Current Assets came in at $1.4 million in Q1 2026, down 2.05% YoY from $1.4 million in Q1 2025, and down 0.5% on a QoQ basis from $1.4 million in Q4 2025.
Intensity Therapeutics (INTS) Non-Current Assets (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Non-Current Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 2.05% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 1.6% YoY) and the FY2025 annual result came in at $1.4 million, down 1.97% from the prior year.
- Non-Current Assets fell to $1.4 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.8 million in Q4 2023 to a low of $167738.0 in Q2 2023.
- A 5-year average of $1.1 million and a median of $1.4 million in 2025 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 687.66% in 2024, down 22.45% in 2024.
- Tracing INTS's Non-Current Assets over 5 years: stood at $306000.0 in 2022, then soared by 498.37% to $1.8 million in 2023, then dropped by 22.45% to $1.4 million in 2024, then fell by 1.97% to $1.4 million in 2025, then decreased by 0.5% to $1.4 million in 2026.
- The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 292,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 292,000.00 |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.83 Mn |
| Sep 30, 2023 | 181,043.00 |
| Jun 30, 2023 | 167,738.00 |
| Dec 31, 2022 | 306,000.00 |